LY75 and neoplasm: Other studies incorporated DC-targeted vaccines that facilitate cross-presentation of tumor antigens, such as the anti-DEC205/HER2 fusion antibody [26], and the gp96-Ig chaperone-secreting IMPACT cell-based vaccine [27].